The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule

Status Completed

Clinical Trial Summary

As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD). According to the result of the phase II study, the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. So the study hypothesis is also that SaiLuoTong capsule will be effective in the treatment of patients with VaD and will be well tolerated. The purpose of the study is to confirm the efficacy and safety of SaiLuoTong capsule on patients with mild to moderate VaD. The outcome measures include general cognitive function, executive function, daily living skills, and mental behavior changes of symptoms in VaD patients.

Clinical Trial Description

Vascular dementia (VaD) is a clinical syndrome of acquired intellectual and functional impairment that results from cerebrovascular diseases. SaiLuoTong capsule is a traditional Chinese medicine compound; it is composed of ginseng extract (the main composition: ginseng total saponins), ginkgo biloba extract (the main composition: YinXingTong ester) and safflower extract (the main composition: the west safflower total glycosides). The function of SaiLuoTong capsule is Yiqi Huoxue and Huayu Tongluo in Chinese traditional medicine theory. Pharmacodynamics studies showed that SaiLuoTong capsule can significantly improve neurological symptoms caused by focal cerebral ischemia in animals, and learning and memory ability in animal models of VaD. The result of the phase II study showed that the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. Based on these previous evidences, the investigators conduct this study to further confirm the efficacy and safety of SaiLuoTong capsule in patients with mild to moderate VaD. This study is a phase III clinical trial of SaiLuoTong capsule for treatment of vascular dementia. The study is a 52-week, multicentre, randomized, double -blind, placebo-controlled study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03789760
Study type	Interventional
Source	Shineway Pharmaceutical Co.,Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	April 10, 2019
Completion date	May 19, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04567745` - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers	Phase 1
Recruiting	`NCT04109963` - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment	Phase 2
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Not yet recruiting	`NCT06416371` - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Completed	`NCT01761227` - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia	Phase 2
Active, not recruiting	`NCT01208675` - The Swedish BioFINDER Study
Completed	`NCT00165763` - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia	Phase 4
Completed	`NCT00621647` - Seroquel- Agitation Associated With Dementia	Phase 3
Recruiting	`NCT04095962` - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia	N/A
Recruiting	`NCT03275363` - The University of Hong Kong Neurocognitive Disorder Cohort	N/A
Active, not recruiting	`NCT03804229` - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia	Phase 3
Enrolling by invitation	`NCT03724136` - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study	N/A
Completed	`NCT02453932` - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia	Phase 3
Completed	`NCT00947531` - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia	Phase 4
Not yet recruiting	`NCT03702543` - Managing Vascular Dementia Risk Factors With SymTrend	Phase 1
Enrolling by invitation	`NCT02147652` - Personalized Music Therapy and Agitation in Dementia	N/A
Recruiting	`NCT04114994` - Longitudinal Cognitive Assessment by BoCA
Recruiting	`NCT06034509` - Cognitive and Vascular Functioning Following TBI
Recruiting	`NCT05921266` - Urolithin A Supplementation in Middle-aged Adults With Obesity	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.